RxDoctor Payments Data

Arif Mahmood, MD

Family Medicine · Wichita Falls, TXNPI 1487940953

Payments from drug & device makers

$424in general payments, 2019–2025

Across 19 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$105
  • Boehringer Ingelheim$80
  • Johnson & Johnson$54
  • Avanir Pharmaceuticals, Inc.$35
  • Novartis$33
  • AstraZeneca$30
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$424 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$843,013
Medicare patients
763
Services billed
8,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,572$447,708
IngrezzaValbenazine Tosylate38$159,597
TrulicityDulaglutide166$147,603
OzempicSemaglutide116$119,229
JardianceEmpagliflozin340$98,559
Cosentyx (2 Syringes)Secukinumab12$93,855
XareltoRivaroxaban259$70,766
JanuviaSitagliptin Phosphate283$53,627
RexultiBrexpiprazole68$49,773
Invega SustennaPaliperidone Palmitate15$48,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$46,389
EntrestoSacubitril/Valsartan149$36,858
NuedextaDextromethorphan Hbr/Quinidine57$36,389
Meropenem151$32,881
LinzessLinaclotide57$32,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$105$464,9381,629 claims
Johnson & JohnsonXarelto, Invega Sustenna, Risperdal Consta$54$136,173287 claims
NovartisCosentyx (2 Syringes), Entresto$33$130,714161 claims
Boehringer IngelheimJardiance$80$98,559340 claims
AbbVieLinzess, Vraylar$21$60,177122 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$49,77368 claims
Avanir Pharmaceuticals, Inc.Nuedexta$35$36,38957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →